Document 0353
 DOCN  M9620353
 TI    The NCI's AIDS antiviral drug screening program.
 DT    9602
 AU    Yang SS; Antiviral Evaluation Branch, National Cancer Institute,
       Bethesda,; MD 20892, USA.
 SO    Leukemia. 1995 Oct;9 Suppl 1:S9-11. Unique Identifier : AIDSLINE
       MED/96022211
 AB    The Developmental Therapeutics Program (DTP) in the National Cancer
       Institute has an unique mission by serving as a resource for all
       academic and private research institutions, the National Institutes of
       Health in the USA, and the global scientific community in the quest for
       effective therapeutic agents for treating patients with Acquired Immune
       Deficiency Syndrome (AIDS) as well as for cancer patients. This
       communication will concentrate on the developmental therapeutic program
       on anti-AIDS drug discovery.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Antiviral
       Agents/*TOXICITY  Cell Fusion  Cell Survival/DRUG EFFECTS  Drug
       Screening/*METHODS  Human  HIV/*DRUG EFFECTS  HIV Infections/*DRUG
       THERAPY  HIV-1/*DRUG EFFECTS/PHYSIOLOGY  *National Institutes of Health
       (U.S.)  United States  Virus Replication/DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).